10-Q: Dalrada Financial Reports Widening Losses and Significant Liquidity Concerns in Q2 2025

Sentiment:

Quarterly Report 21 July 2025 5:07 PM

Dalrada Financial Corporation reported a substantial increase in net loss and a worsening working capital deficit for the six months ended December 31, 2024, raising significant doubt about its ability to continue as a going concern.

Capital raiseThe company will be required to raise substantial capital to fund capital expenditures, working capital, and other cash requirements.Management plans to obtain operational liquidity through successful financing via equity and/or debt investors.The company will continue to rely on equity sales of common shares to fund business operations.Proceeds from related party notes payable amounted to $2,367,759 for the six months ended December 31, 2024.Proceeds from private placement were $604,000 for the six months ended December 31, 2023.Proceeds from stock issuance were $781,669 for the six months ended December 31, 2024.The company entered into a Loan and Security Agreement with Nautilus Funding Solutions, LLC Series XIII on February 25, 2025, for a maximum drawdown of $1,500,000, with $1,170,000 drawn on February 28, 2025.The company entered into a Loan Agreement with NFS XIII and AMS Capital Solutions, LLC on June 13, 2025, for a total of $600,000, with $500,000 drawn on June 16, 2025.

Worse than expectedThe net loss significantly widened to $13,546,077 for the six months ended December 31, 2024, compared to $11,834,412 in the prior year period.The working capital deficit substantially increased to $13,331,247 as of December 31, 2024, from $7,085,306 on June 30, 2024.Cash and cash equivalents decreased by over 72% during the six months ended December 31, 2024.Interest expense surged dramatically, indicating increased borrowing costs or debt levels.The company explicitly states that its net loss and limited working capital raise substantial doubt about its ability to continue as a going concern.

Summary

Total revenues for the six months ended December 31, 2024, were $9,145,513, a slight decrease from $9,375,396 in the same period of 2023.
Net loss for the six months ended December 31, 2024, significantly widened to $13,546,077, compared to a net loss of $11,834,412 for the same period in 2023.
The company's working capital deficit increased to $13,331,247 as of December 31, 2024, from $7,085,306 as of June 30, 2024.
Cash and cash equivalents decreased to $139,756 as of December 31, 2024, from $501,927 as of June 30, 2024.
Interest expense surged to $2,099,614 for the six months ended December 31, 2024, up from $327,153 in the prior year period.
Genefic segment revenue increased by 32.5% to $6,203,531 for the six months ended December 31, 2024, primarily due to sales activity and increased collections.
Dalrada Precision Manufacturing revenue decreased by 88.2% to $252,609 for the six months ended December 31, 2024, due to project finalization and reduced sales.
The company acquired Grand Entrances on August 21, 2024, for $100 cash and contingent consideration of $211,289, aiming to integrate custom door and hardware products into Bothof Brothers' construction pipelines.
Dalrada Career Institute (DCI) started its first RN nursing class in February 2024, with completion expected in December 2024, and intends to double class size in 2025.
The company's EIDL loan is technically in default due to a change in ownership without SBA consent, with a balance of $143,421 as of December 31, 2024.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a widening net loss, a significantly increased working capital deficit, and rapidly depleting cash reserves. The explicit 'going concern' warning, coupled with a substantial increase in interest expense and reliance on related party funding, indicates a highly precarious financial position. While some segments show revenue growth, the overall financial health is deteriorating, warranting a very low sentiment score.

Positives

Genefic segment revenue increased by 32.5% to $6,203,531 for the six months ended December 31, 2024, driven by increased sales activity and collections.
Dalrada Climate Technology revenue increased by 6.4% to $1,971,522 for the six months ended December 31, 2024, primarily due to construction projects for Bothof Brothers Construction.
Dalrada Technology Spain (DTS) showed significant revenue growth, increasing to $412,244 for the six months ended December 31, 2024, from $44,349 in the prior year.
The acquisition of Grand Entrances is expected to vertically integrate custom door and hardware products into Bothof Brothers' real estate construction pipelines, potentially scaling profit margins.
Dalrada Career Institute (DCI) launched its first RN nursing class in February 2024 and plans to double class size in 2025, indicating growth in its educational programs.

Negatives

Net loss significantly widened to $13,546,077 for the six months ended December 31, 2024, compared to $11,834,412 in the prior year period.
The working capital deficit increased substantially to $13,331,247 as of December 31, 2024, from $7,085,306 as of June 30, 2024.
Cash and cash equivalents decreased by over 72% from $501,927 to $139,756 during the six months ended December 31, 2024.
Interest expense dramatically increased to $2,099,614 for the six months ended December 31, 2024, from $327,153 in the same period of 2023.
Genefic segment revenue decreased by 38.6% for the three months ended December 31, 2024, due to limited working capital and a shift in sales pipelines.
Dalrada Precision Manufacturing revenue decreased by 88.2% for the six months ended December 31, 2024, due to project finalization and reduced sales activity.
The company's EIDL loan is technically in default due to a change in ownership without SBA prior written consent.
Operating expenses for Genefic increased by 43.1% for the six months ended December 31, 2024, due to increased activity and consulting-related expenses.
The company's disclosure controls and procedures were deemed not effective as of December 31, 2024.

Risks

The company's net loss and limited working capital raise substantial doubt about its ability to continue as a going concern.
Continuation as a going concern is dependent on successful financing through equity and/or debt investors and growing profitable subsidiaries.
There is no assurance that the company will obtain additional financing through private placements and/or public offerings necessary to support working capital requirements.
The company may incur additional losses in the foreseeable future until it can successfully execute its business plan.
Increased costs are being incurred as a result of being a publicly traded company, including legal, accounting, and compliance expenses.
The EIDL loan is technically in default due to a change in ownership without SBA prior written consent, posing a risk to the loan's terms.
The company is involved in multiple legal proceedings, including lawsuits for misappropriation of funds, breach of contract, and labor law violations, which could result in significant liabilities.
Changes in the fair value of contingent earn-out consideration could cause a material impact and volatility in operating results.
The effectiveness of disclosure controls and procedures was concluded to be not effective, indicating potential risks in financial reporting and compliance.

Future Outlook

The company anticipates needing additional liquidity over the next twelve months to fund operations, expand subsidiaries, grow pharmacies, commercialize DCT heat pump units, and expand Bothof Brothers Construction's development footprint. Management plans to support operations by raising capital and accelerating sales and marketing efforts for high-margin products. The continuation of the company as a going concern is dependent on continued financial support from management, ability to obtain necessary debt or equity financing, and generating profitable operations.

Management Comments

Our net loss and limited working capital raise substantial doubt about our ability to continue as a going concern.
We will be required to raise substantial capital to fund our capital expenditures, working capital, and other cash requirements.
We will continue to rely on related parties and seek other financing to complete our business plans.
We anticipate needing additional liquidity during the next twelve months to fund operations, expand our subsidiaries, expand the growth of the pharmacies, continue the commercialization of our DCT heat pump units and expanding Bothof Brothers Constructions development footprint.
Management is planning to support operations by raising capital, and by accelerating sales & marketing efforts of high-margin DCT heat pump units, precision parts, DepTecs deposition systems and COVID-19 testing.

Industry Context

Dalrada operates across diverse sectors including healthcare (Genefic), climate technology (Dalrada Climate Technology), precision manufacturing, and information technology (Dalrada Technologies). The healthcare segment, particularly Genefic, experienced a revenue decline in the recent quarter due to working capital limitations and sales pipeline shifts, contrasting with its six-month growth. The climate technology segment showed growth, indicating potential alignment with increasing demand for sustainable solutions. The significant decline in precision manufacturing revenue suggests challenges in project finalization and sales. The company's reliance on related party funding and its going concern warning highlight a challenging financial environment across its varied business lines, potentially indicating difficulty in securing traditional financing within these competitive industries.

Comparison to Industry Standards

The document does not provide specific industry benchmarks or comparable companies to assess the results in the context of global standards. Therefore, a detailed comparison is not possible based solely on the provided information.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Internal Control Deficiency	The Chief Executive Officer and Principal Financial Officer concluded that disclosure controls and procedures were not effective to provide reasonable assurance that required information is recorded, processed, summarized, and reported within specified time periods.	2024-12-31	This indicates a significant weakness in financial reporting oversight and compliance, potentially leading to misstatements or delays in future filings. It raises concerns about the reliability of financial information and adherence to regulatory requirements.

Legal Proceedings

A lawsuit filed by Genefic Products (Dalrada Health) against Vivera Pharmaceuticals, Inc. and Paul Edalat for misappropriation of $2,104,509 was dismissed on January 13, 2025.
Lawsuits filed by Kroger Specialty Pharmacy LLC against Genefic Specialty Pharmacy and two employees regarding non-compete clauses were settled and dismissed on March 19, 2025. A preliminary injunction against one employee in Tennessee is due to expire in April 2025.
Asset Group, Inc. filed a breach of contract suit against Dalrada Health Products (DHP) for $3,240,000 related to face mask purchases; DHP filed a cross-complaint for tortious interference seeking the same amount. A jury trial is scheduled for September 19, 2025.
MDIQ filed a breach of contract suit against Dalrada Financial Corporation (DFCO) for unpaid insurance claims; DFCO is counter-suing for approximately $2,000,000 in unpaid claims. No trial date has been set.
DFCO filed a lawsuit against Simon Gray and DePrey Company for breach of contract and intentional interference with contractual relationships related to Fastenal Company purchase orders. No trial date has been set.
DFCO filed a lawsuit against Stuart Cox in June 2024 for fraud, breach of contract, and unjust enrichment related to the acquisition of Likido company. Settlement negotiations are ongoing.
DFCO filed a lawsuit on November 19, 2024, against William Bonar, Samantha and Ian MacKenzie, Jillian Hughes, and Marion Bonar for fraud, tortious interference, and misappropriation of trade secrets. No trial date has been set.
FFF Enterprises filed a lawsuit on November 27, 2024, against Genefic, Inc. and DFCO for alleged breach of a service agreement, demanding $564,743.48. Settlement negotiations are ongoing.
A former employee filed a complaint on June 20, 2024, alleging labor law violations; a jury trial is scheduled for October 10, 2025.
Lamie RB Investments, LLC filed a suit on March 27, 2025, against Genefic, Inc. for breach of a lease contract, seeking damages equal to the lease term.

Related Party Transactions

The company received cash funding or expenses paid on its behalf from related parties totaling $2,367,759 for the six months ended December 31, 2024, and $1,854,380 for the same period in 2023.
Promissory notes were created quarterly for these related party fundings, with remaining amounts included in accounts payable related parties.
Accounts payable and accrued liabilities related parties increased by $3,039,058 to $5,962,476 as of December 31, 2024, primarily due to payroll-related expenditures.
Notes payable related parties increased significantly to $2,421,716 as of December 31, 2024, from $53,957 on June 30, 2024.
Related party revenues for the six months ended December 31, 2024, were $525,778, primarily from Bothof Brothers ($525,778), with minor contributions from Dalrada Energy Services ($354), Ignite ($140), and Prakat ($15,000).
Conversion of related party debt principal and interest into Series I Convertible Preferred Stock occurred on March 29, 2024 ($13,318,783 converted into 15,951 shares) and June 30, 2024 ($3,924,499 converted into 4,700 shares).
On October 3, 2024, 781,670 shares of common stock related to SSCe Valuation Shortfall were converted to 156 shares of Series I Stock.
On October 14, 2024, 4,596 shares of Series I Stock were converted to 22,981,670 shares of common stock.

Stakeholder Impact

Shareholders face significant dilution risk from ongoing equity sales and conversions of preferred stock and debt into common shares.
Shareholders are exposed to substantial financial risk due to the company's widening net loss, increasing working capital deficit, and explicit 'going concern' warning.
Employees and consultants are impacted by stock-based compensation plans, which represent a significant non-cash expense.
Creditors, particularly related parties, are providing substantial financial support through notes payable and cash funding, indicating their critical role in the company's liquidity.
Customers may experience service disruptions or changes in product availability if the company's financial challenges impact operations or product development.
Legal proceedings involving former employees, suppliers, and other entities could result in financial liabilities or reputational damage.

Next Steps

Obtain operational liquidity through collection of outstanding accounts receivable from medical insurance providers, Medicare, and pharmaceutical sales.
Accelerate sales and marketing efforts for DCT commercial and residential heat pumps.
Continue ongoing projects through Bothof Brothers, Dalrada Technology Spain, and Deposition Technologies.
Raise additional capital through equity and/or debt investors.
Double the class size for the RN nursing program at Dalrada Career Institute in 2025.
Finalize the transfer of ownership for the EIDL loan with the SBA to address the default status.
Continue discovery in ongoing legal proceedings, including the Asset Group, Inc. case, MDIQ case, Simon Gray/DePrey Company case, and the lawsuit against William Bonar et al.
Engage in settlement negotiations for the lawsuit filed by FFF Enterprises and the case against Stuart Cox.
Conduct in-depth discovery for the former employee's labor law violation complaint.
Address the breach of lease contract suit filed by Lamie RB Investments, LLC.

Key Dates

Date	Description
2020-07-09	Board authorized the Dalrada Financial Corp 2020 Stock Compensation Plan.
2021-02-25	Company amended the 2020 Stock Compensation Plan to issue up to 4,500,000 shares.
2021-08-29	Dalrada entered a joint venture with Vivera Pharmaceuticals, Inc. for a 51% ownership and controlling interest to operate a CLIA-certified diagnostics lab.
2021-11-10	Company cancelled 6,500,000 shares issued to the Board of Directors and issued 6,500,000 cashless warrants.
2021-11-30	Company issued 2,275,000 cashless warrants to employees and consultants.
2021-12-31	Dalrada Health filed suit against Vivera and Paul Edalat for misappropriation of funds.
2022-02-16	Company issued 2,250,000 cashless warrants to new Board of Directors members.
2022-04-06	Acquisition agreement dated between the Company and Silicon Services Consortium Ltd. (SSCe).
2022-08-11	Company issued 2,200,000 cashless warrants to new Board of Directors and Advisors members.
2022-10-07	Company issued 3,000,000 cashless warrants to the selling shareholder of Bothof in connection with acquisition.
2023-03-01	Company issued 1,000,000 cashless warrants to the selling shareholders of Dalrada Technology Ltd with the acquisition.
2023-04-14	Company authorized and issued 26,638,500 cashless warrants to various officers, employees, and consultants.
2023-05-25	Company authorized and issued 587,634 cashless warrants to various employees.
2023-06-23	$29,315,320 of related party debt principal and interest converted into 35,108 shares of Series I Convertible Preferred Stock.
2023-06-26	Company renewed a loan for $176,836.
2023-07-25	Company entered into an agreement with OnPoint LTB, LLC, for a credit line and funding of up to $2,000,000.
2023-09-06	Company authorized and issued 15,861,000 cashless warrants to various officers, employees, and consultants.
2023-09-30	Kroger Specialty Pharmacy LLC filed lawsuits/preliminary injunctions against Genefic Specialty Pharmacy and two employees.
2023-09-30	Asset Group, Inc. filed a breach of contract with Dalrada Health Products (DHP).
2023-10-04	Remaining $800,000 of the OnPoint LTB, LLC credit line was borrowed.
2023-12-14	Company authorized and issued 250,000 cashless warrants to various employees.
2024-01-04	Company executed a revenue purchase agreement with NewCo Capital Group LLC for $350,000.
2024-01-30	Company authorized and issued 5,455,000 cashless warrants to various employees and consultants.
2024-02-29	Company issued 4,666,665 shares of common stock related to a private placement for $604,001.
2024-02-29	Company issued 1,200,000 shares of common stock pursuant to consulting agreements.
2024-03-29	$13,318,783 of related party debt principal and interest converted into 15,951 shares of Series I Convertible Preferred Stock.
2024-03-31	MDIQ filed a breach of contract with Dalrada Financial Corporation (DFCO).
2024-04-08	Company entered into a promissory note with 1800 Diagonal Lending, LLC for $172,500.
2024-04-18	Company board of directors approved to increase the maximum draw down to $8,000,000 for Nautilus Parent Holding, LLC loan.
2024-04-30	Court in Tennessee case granted preliminary injunction on Tennessee employee, due to expire April 2025.
2024-05-02	Company executed a revenue purchase agreement with Credit Line Capital Group for $600,000.
2024-05-13	Company acquired 100% of IV Services, LLC dba Genefic Infusion Rx (IVS).
2024-05-16	Company entered into a promissory note with 1800 Diagonal Lending, LLC for $122,475.
2024-05-16	Company entered into a term loan with Agile Capital Funding, LLC for $525,000.
2024-05-22	Valuation Shortfall shares from SSCe acquisition were issued into 4,440 shares of Series I Convertible Preferred Stock.
2024-06-20	A former employee filed a complaint alleging numerous labor law violations.
2024-06-25	Company executed a revenue purchase agreement with Cucumber Capital LLC for $325,000.
2024-06-30	Company converted $3,924,499 of related party debt principal and interest into 4,700 shares of Series I Convertible Preferred Stock.
2024-07-10	Company entered into a promissory note with 1800 Diagonal Lending, LLC for $87,975.
2024-07-21	Company executed a cash advance agreement with Cali Flower Capital Inc. for $200,000.
2024-07-21	Registrant's outstanding stock consisted of 120,157,113 common shares.
2024-07-25	Company executed a revenue purchase agreement with 24 Capital for $125,000.
2024-07-29	Company executed a revenue purchase agreement with Tycoon Capital Group for $125,000.
2024-08-21	Company acquired 100% of Grand Entrances through a Purchase Agreement.
2024-08-23	Company executed a revenue purchase agreement with Quick Funding for $170,000.
2024-09-20	Company executed a revenue purchase agreement with QFS Capital, LLC for up to $1,573,781.
2024-10-03	Company converted an additional 781,670 shares of common stock related to SSCe Valuation Shortfall shares to 156 shares of Series I Stock.
2024-10-14	Company converted 4,596 shares of Series I Stock to 22,981,670 shares of its common stock.
2024-10-31	Grand Entrances assigned its lease to Bothof Brothers for retail showroom and warehouse space in San Diego, California.
2024-11-19	DFCO filed a lawsuit against William Bonar, Samantha and Ian MacKenzie, Jillian Hughes and Marion Bonar.
2024-11-27	FFF Enterprises filed a lawsuit against Genefic, Inc. and DFCO.
2024-12-31	End of the quarterly period covered by this Form 10-Q.
2025-01-13	Lawsuit between Dalrada Health and Vivera Pharmaceuticals, Inc. dismissed by Orange County Superior Court.
2025-01-15	DHP filed a cross-complaint against Asset Group and Dimco Holdings.
2025-02-20	Suit between Dalrada Health and Vivera Pharmaceuticals, Inc. dismissed through the Orange County Superior Court of California.
2025-02-25	Company entered into a Loan and Security Agreement with Nautilus Funding Solutions, LLC Series XIII (NFS XIII).
2025-02-28	Company drew down $1,170,000 on the Loan and Security Agreement with NFS XIII.
2025-03-19	Lawsuits between Kroger Specialty Pharmacy LLC and Genefic Specialty Pharmacy were settled and dismissed.
2025-03-27	Lamie RB Investments, LLC filed a suit for breach of a lease contract with Genefic, Inc.
2025-06-13	Company entered into a Loan Agreement with NFS XIII and AMS Capital Solutions, LLC for a total loan amount of $600,000.
2025-06-16	Company drew down $500,000 on the Loan Agreement with NFS XIII and AMS Capital Solutions, LLC.
2025-07-07	Company filed a lawsuit against Wells Fargo.
2025-07-21	Date of filing of the Form 10-Q.
2025-09-19	Jury trial scheduled for the Asset Group, Inc. vs. DHP case.
2025-10-10	Jury trial scheduled for the former employee's labor law violation complaint.

Recommendation

strong sell

Keywords

Financial Services, Healthcare, Climate Technology, Precision Manufacturing, Information Technology, SEC Filing, 10-Q, Quarterly Report, Net Loss, Working Capital Deficit, Going Concern, Debt, Equity, Acquisitions, Legal Proceedings, Related Party Transactions

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.